The Joint Committee on Vaccination and Immunisation (JCVI) is currently in the process of estimating the cost of treating shingles and post herpetic neuralgia (PHN) within the wider context of the benefits of shingles vaccination, including whether a vaccination programme would be cost effective. It will provide advice in due course.